Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033332 · ClinicalTrials.gov registry record · Phase 3
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
NCT00033332: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00033332 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00033332, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining dexamethasone and thalidomide may kill more cancer cells. It is not yet known whether dexamethasone is more effective with or without thalidomide in treating multiple myeloma. PURPOSE: Randomized phase III trial to determine the effectiveness of dexamethasone with or without thalidomide in treating patients who have multiple myeloma.
Interventions
- DRUG dexamethasone
- DRUG thalidomide
- DRUG zoledronic acid
- DRUG pamidronate disodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
What the finished NCT00033332 record still lists
NCT00033332 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which dexamethasone is the first listed.
NCT00033332 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00033332 about?
NCT00033332 is a clinical study titled "Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining dexamethasone and thalidomide may kill more cancer cells. It is not yet known whether dexa...
What is the current status of trial NCT00033332?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-04. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00033332?
The interventions under investigation include: dexamethasone (DRUG), thalidomide (DRUG), zoledronic acid (DRUG), pamidronate disodium (DRUG).
Who is sponsoring clinical trial NCT00033332?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia